NEW YORK, September 6, 2026, 2:55 a.m. EDT — Rocket Lab Corp. NASDAQ:RKLB Chief Financial Officer Adam Spice sold 140,157 shares for $8.78 million on Wednesday. The trade sounds bearish in isolation. The regulatory filing tells a more measured story.
Spice first exercised 140,157 employee options at $1.09 each, then sold exactly the same number of newly received shares at a $62.63 weighted average. His direct common-stock position finished at 1,155,967 shares, precisely where it stood before the exercise.
The Form 4 filed Friday says the sales “occurred automatically” under a Rule 10b5-1 plan adopted June 3. Execution was scheduled three months earlier, limiting what Wednesday’s timing can reveal about management’s latest view.
One economic reduction did occur: Spice surrendered 140,157 options and converted their value to cash.
What actually moved through the account
The option exercise and both same-day sales reported for September 2.
TS2 calculation from Rocket Lab’s Form 4. Taxes, fees and any withholding are excluded.
The two sale blocks carried weighted prices of $62.2564 and $62.9704. Gross proceeds were $8.78 million before a $152,771 exercise cost, leaving an $8.62 million spread before taxes and fees.
Rocket Lab shares closed Friday at $64.26, up 0.71% and 2.6% above Spice’s blended sale price. The market has moved against the sale for two sessions.
The sale came after a 24% retreat
Daily closes over the latest 25 U.S. trading sessions.
Last market close at . Source: Yahoo Finance historical data. Prices are rounded.
The rebound remains modest: Friday’s close was 22.4% below the August 7 monthly peak and 57.4% beneath Nasdaq’s $151 52-week high.
Spice’s remaining exposure is much larger than the cash sale. He still reported 1,155,967 directly owned shares and another 250,000 through a trust. Those common holdings were worth about $90.3 million at Friday’s close.
The same filing lists 2,382,668 remaining options with a $1.09 strike and an August 2028 expiry, carrying about $150.5 million of gross intrinsic value at $64.26. That figure excludes tax and says nothing about when another sale may occur.
What remained after the sale
Common holdings use Friday’s $64.26 close. Option value is gross intrinsic value.
Source: SEC Form 4 and TS2 calculations. Market values are snapshots, not realizable net proceeds.
The exercise represented just 0.023% of Rocket Lab’s 598.18 million shares outstanding on June 30. The company’s reported count had risen 10.1% since December 31, a far larger dilution measure.
Operations carry more weight: Rocket Lab reported record second-quarter revenue of $234.1 million and a $49.3 million net loss. First-half operating cash use reached $134.4 million, while cash stood at $2.13 billion.
“We achieved a record $234 million in Q2 revenue,” Chief Executive Peter Beck said in the August earnings release. Backlog reached $2.36 billion. Third-quarter revenue guidance runs from $250 million to $265 million.
That growth has a demanding price, with Nasdaq putting Rocket Lab’s market capitalization near $38.5 billion. The figure equals roughly 41 times annualized second-quarter revenue and 16 times reported backlog.
Analysts remain bullish despite the gap: Nasdaq’s summary shows a mean Buy rating from 11 firms and a $115 one-year target. That target sits 79% above Friday’s close.
The useful investor test now lies elsewhere: Neutron’s schedule, order conversion and acquisition execution. A pre-arranged option sale changes none of those milestones. Fresh insider sales that consume existing common holdings would carry a different signal.
Risks remain high. Rocket Lab is still loss-making, and launch delays can move revenue between quarters. Its valuation leaves the shares exposed to slower bookings, cost overruns or further dilution.
